Emerging Biotech Saved Over $300,000 on Phase I Oncology Trial with Slope

This emerging biotech was facing operational difficulties within its Phase 1 Oncology programs because of its complicated designs and sample requirements. Each study had an intricate network of clinical sites, a detailed clinical sample schema, multiple external sample destinations, and required shipping conditions. This was compounded by economic pressures and supply chain inefficiencies during the COVID pandemic. Read the case study to learn how this organization saved over $300k by leveraging Slope's clinical trial execution platform.